Daidzin and its de‐glycosylated constituent daidzein as a potential therapeutic for cardiovascular diseases: A review from bench to bed

Abstract Continuing research is being conducted on novel preventive and therapeutic drugs for cardiovascular diseases (CVDs). Daidzein has shown potential beneficial effects regarding various CVDs and risk factors. However, data in this regard are inconsistent, and there is an urge to accumulate. Therefore, we reviewed the effects of daidzein and daidzin on CVDs. We conducted a search through Scopus, PubMed, Google Scholar, and Web of Science from inception up to October 2023 to find studies with the primary intention of assessing the impacts of daidzein and daidzin on cardiovascular disease in various in vitro, animal, and clinical settings. In vitro and animal studies showed that daidzein and daidzin are effective in terms of reducing inflammation, oxidative stress, hyperlipidemia, myocardial infarction, thromboembolism, hypertension, and aneurysms. However, clinical studies only confirmed a relatively small portion of the previous findings of the in vitro and animal investigations, including anti‐hyperlipidemic effects. In conclusion, in vitro and animal studies have reported potential therapeutic effects for daidzein and daidzin regarding CVDs. However, most of the clinical studies were unable to exhibit the same results. Hence, further clinical studies are required to determine the outcomes of administering daidzein and its derivatives for an extended period and in various doses.